Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.51 |
| ▸ | MET | P08581 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ATR | Q13535 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1798727 | 1.00 | ALK (0.54) | ALKHRH3METL3MBTL1MAPT | |
| Trifluoroacetic Acid SCHEMBL1800258 | 0.98 | ALK (0.54) | ALKHRH3METL3MBTL1MAPT | |
| Trifluoroacetic Acid SCHEMBL1800256 | 0.98 | ALK (0.54) | ALKHRH3METL3MBTL1MAPT | |
| SCHEMBL1799080 | 0.94 | HRH3 (0.56) | HRH3METL3MBTL1MAPTKDM4E | |
| SCHEMBL1799082 | 0.94 | HRH3 (0.56) | HRH3METL3MBTL1MAPTKDM4E | |
| Trifluoroacetic Acid SCHEMBL1795597 | 0.93 | ALK (0.49) | ALKHRH3METL3MBTL1MAPT | |
| Trifluoroacetic Acid SCHEMBL1795599 | 0.93 | ALK (0.49) | ALKHRH3METL3MBTL1MAPT | |
| SCHEMBL12616094 | 0.92 | HRH3 (0.56) | HRH3METL3MBTL1MAPTATR | |
| SCHEMBL12615763 | 0.92 | HRH3 (0.56) | HRH3METL3MBTL1MAPTATR | |
| SCHEMBL1799463 | 0.91 | HRH3 (0.57) | HRH3METL3MBTL1MAPTATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1861360-B1 | PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-12-02 | — | — | EP | claimed |
| EP-1861360-A1 | PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-05 | — | — | EP | claimed |
| WO-2006101808-A1 | PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | WO | claimed |
| US-7951826-B2 | Obesity; cognition activators; narcolepsy | ELI LILLY AND COMPANY (US) | 2011-05-31 | — | — | US | disclosed |
| EP-1861360-B1 | PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080207732-A1 | Pyrrolidine Derivatives as Histamine H3 Receptor Antagonists | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| EP-1861360-A1 | PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006101808-A1 | PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207732-A1 | Pyrrolidine Derivatives as Histamine H3 Receptor Antagonists | HRH3, HCRTR1, HRH4 | ALK 889/4885HRH3 1/4885MET 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.